Beihai Kangcheng-B Exceeds 35% in Trading, Cumulative Increase of Over 13-Fold This Year! Founder of Beihai Kangcheng: Rare Diseases Differ from Common Ones, and Basic National Insurance Alone Cannot Solve Patients' Payment Problems

Beihai Kangcheng-B (01228) has exceeded 35% in trading, with a cumulative increase of over 13-fold this year. As of the date of publication, the stock price has risen by 31.85%, currently standing at HK$1.78, with a transaction volume of HK$425,590,000.

On May 15th, the National Medical Products Administration approved Beihai Kangcheng's application for the marketing approval of injectable velaspherase beta (trade name: Gorenin) through the priority review and approval program. This product is suitable for long-term enzyme replacement therapy in patients with I-type and III-type glycogen storage disease aged 12 or above, including children and adults.

The founder of Beihai Kangcheng, chairman, and CEO stated that rare diseases differ from common ones, and basic national insurance alone cannot solve patients' payment problems. Beihai Kangcheng is actively communicating with the medical insurance payment department to hope that Gorenin's case will provide support for a new more feasible payment mechanism for rare diseases in China.